Skip to content

Legal status · United States

Is Trametinib legal in the United States?

Written by Reviewed Sep 2026

ApprovedLongevityNo human studies cited

Direct answer

Yes. Trametinib is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, no human study is cited on its profile.

Trametinib in the United States at a glance

ClassificationFDA-approved, prescription only
NoteApproved for BRAF-mutant cancers. Carries substantial toxicity including cardiomyopathy, retinopathy, skin toxicity and haemorrhage. No ageing indication.
FDA approval statusFDA-approved as Mekinist for BRAF-mutant melanoma and other BRAF-mutant cancers, usually combined with dabrafenib. Not approved for any ageing indication.
Human studies cited0 of 1 citations on the profile
ReviewedSep 2026

Classification and note come from the Trametinib profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.

What this means

  • 01

    FDA has approved Trametinib for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.

  • 02

    Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.

  • 03

    Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.

What Trametinib is

An approved melanoma drug that extended mouse lifespan, and did so additively with rapamycin, which suggests the two pathways are separate levers rather than the same one.

Most compounds that extend lifespan in mice are thought to work through nutrient sensing, which means adding them together should produce little more than either alone. Trametinib is interesting because it appears not to fit that pattern.

Mechanism: A selective allosteric inhibitor of MEK1 and MEK2, the kinases immediately downstream of RAF in the Ras, RAF, MEK, ERK cascade. That cascade transmits growth factor signals to the nucleus and drives proliferation, and it is constitutively active in cancers with BRAF mutations, which is the basis of the approval.

Regulatory history: FDA-approved as Mekinist for BRAF-mutant melanoma and other BRAF-mutant cancers, usually combined with dabrafenib. Not approved for any ageing indication.

How FDA treats this kind of product

Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.

The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Trametinib at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

Trametinib in other countries

Frequently asked questions

Is Trametinib legal in the United States?

Yes. Trametinib is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, no human study is cited on its profile. Note: Approved for BRAF-mutant cancers. Carries substantial toxicity including cardiomyopathy, retinopathy, skin toxicity and haemorrhage. No ageing indication.

Can I buy Trametinib in the United States?

Only with a prescription. Trametinib is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Approved for BRAF-mutant cancers. Carries substantial toxicity including cardiomyopathy, retinopathy, skin toxicity and haemorrhage. No ageing indication.

Is Trametinib FDA approved?

Yes. FDA status: FDA-approved as Mekinist for BRAF-mutant melanoma and other BRAF-mutant cancers, usually combined with dabrafenib. Not approved for any ageing indication.. Current US classification: "FDA-approved, prescription only". On the evidence, no human study is cited on its profile.

Related compounds in the United States

Full research profile

Mechanism, cited studies, FDA status and the full legal summary for Trametinib live on its compound profile.

Trametinib profile

This page is general information about the regulatory status of Trametinib in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.